Patents by Inventor Md. Nasrul Hoda

Md. Nasrul Hoda has filed for patents to protect the following inventions. This listing includes patent applications that are pending as well as patents that have already been granted by the United States Patent and Trademark Office (USPTO).

  • Publication number: 20220062262
    Abstract: Stroke patients with comorbidities, such as diabetes, hypertension, or other conditions associated with cardiovascular, pulmonary or renal disease do not respond well to current treatments for stroke. An inhibitor of S-nitrosoglutathione reductase (GSNOR) is administered as an adjunct therapy with remote ischemic conditioning (RIC) to treat a stroke in a subject having at least one comorbidity, such as diabetes and hypertension. When performed in conjunction with GRI therapy and RIC, intravenous tissue plasminogen activator therapy (IVT) for thrombolysis and/or endovascular thrombectomy (EVT) for clot retrieval are effective in subjects with comorbidities, even after five hours post-onset of stroke.
    Type: Application
    Filed: April 16, 2021
    Publication date: March 3, 2022
    Inventors: Syed Kashif ZAIDI, Md. Nasrul HODA, Muhammad Hussain AL-QAHTANI
  • Publication number: 20220062264
    Abstract: Stroke patients with comorbidities, such as diabetes, hypertension, or other conditions associated with cardiovascular, pulmonary or renal disease do not respond well to current treatments for stroke. An inhibitor of S-nitrosoglutathione reductase (GSNOR) is administered as an adjunct therapy with remote ischemic conditioning (RIC) to treat a stroke in a subject having at least one comorbidity, such as diabetes and hypertension. When performed in conjunction with GRI therapy and RIC, intravenous tissue plasminogen activator therapy (IVT) for thrombolysis and/or endovascular thrombectomy (EVT) for clot retrieval are effective in subjects with comorbidities, even after five hours post-onset of stroke.
    Type: Application
    Filed: July 13, 2021
    Publication date: March 3, 2022
    Inventors: Syed Kashif ZAIDI, Md. Nasrul HODA, Muhammad Hussain AL-QAHTANI, Farid Ahmed, Heba Al Khatabi
  • Patent number: 11260051
    Abstract: Stroke patients with comorbidities, such as diabetes, hypertension, or other conditions associated with cardiovascular, pulmonary or renal disease do not respond well to current treatments for stroke. An inhibitor of S-nitrosoglutathione reductase (GSNOR) is administered as an adjunct therapy with remote ischemic conditioning (RIC) to treat a stroke in a subject having at least one comorbidity, such as diabetes and hypertension. When performed in conjunction with GRI therapy and RIC, intravenous tissue plasminogen activator therapy (IVT) for thrombolysis and/or endovascular thrombectomy (EVT) for clot retrieval are effective in subjects with comorbidities, even after five hours post-onset of stroke.
    Type: Grant
    Filed: April 16, 2021
    Date of Patent: March 1, 2022
    Assignee: KING ABDULAZIZ UNIVERSITY
    Inventors: Syed Kashif Zaidi, Md. Nasrul Hoda, Muhammad Hussain Al-Qahtani
  • Patent number: 11246861
    Abstract: Stroke patients with comorbidities, such as diabetes, hypertension, or other conditions associated with cardiovascular, pulmonary or renal disease do not respond well to current treatments for stroke. An inhibitor of S-nitrosoglutathione reductase (GSNOR) is administered as an adjunct therapy with remote ischemic conditioning (RIC) to treat a stroke in a subject having at least one comorbidity, such as diabetes and hypertension. When performed in conjunction with GRI therapy and RIC, intravenous tissue plasminogen activator therapy (IVT) for thrombolysis and/or endovascular thrombectomy (EVT) for clot retrieval are effective in subjects with comorbidities, even after five hours post-onset of stroke.
    Type: Grant
    Filed: July 13, 2021
    Date of Patent: February 15, 2022
    Assignee: KING ABDULAZIZ UNIVERSITY
    Inventors: Syed Kashif Zaidi, Md. Nasrul Hoda, Muhammad Hussain Al-Qahtani, Farid Ahmed, Heba Al Khatabi
  • Patent number: 11071733
    Abstract: Stroke patients with comorbidities, such as diabetes, hypertension, or other conditions associated with cardiovascular, pulmonary or renal disease do not respond well to current treatments for stroke. An inhibitor of S-nitrosoglutathione reductase (GSNOR) is administered as an adjunct therapy with remote ischemic conditioning (RIC) to treat a stroke in a subject having at least one comorbidity, such as diabetes and hypertension. When performed in conjunction with GRI therapy and RIC, intravenous tissue plasminogen activator therapy (IVT) for thrombolysis and/or endovascular thrombectomy (EVT) for clot retrieval are effective in subjects with comorbidities, even after five hours post-onset of stroke.
    Type: Grant
    Filed: August 25, 2020
    Date of Patent: July 27, 2021
    Assignee: KING ABDULAZIZ UNIVERSITY
    Inventors: Syed Kashif Zaidi, Md. Nasrul Hoda, Muhammad Hussain Al-Qahtani